Ascendis Pharma A/S ASND
Ascendis Pharma A/S (Nasdaq: ASND) is a rare genetic drug developer. Its lead program, TransCon CNP (navepegritide), is in Phase 3 for achondroplasia in children. Its next catalyst on record is TransCon CNP (navepegritide): European Commission decision on marketing authorisation application (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TransCon CNP (navepegritide) — European Commission decision on marketing authorisation application (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TransCon CNP (navepegritide) | achondroplasia | unclear | Phase 3 |
Recent results and decisions
- Oct 16, 2026positive CHMP adopts positive opinion recommending EU marketing authorization for once-weekly TransCon CNP for achondroplasia in children aged two years and older with open epiphyses, with EC decision expected in Q4 2026.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and
Filing - Oct 16, 2026adcomm positive CHMP adopts positive opinion recommending marketing authorization for once-weekly TransCon CNP in the EU for treatment of achondroplasia in children two years and older whose epiphyses are not closed.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union.
Filing - Aug 13, 2026positive Week 78 COACH data showed sustained efficacy with no compromise to safety or tolerability; all 21 enrolled children completed 78 weeks and remain on therapy (no numeric efficacy values in this release).
Week 78 COACH Trial data showed sustained unprecedented efficacy over 78 weeks with no compromise to safety or tolerability.
Filing
8 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.